Phase behavior of itraconazole-phenol mixtures and its pharmaceutical applications

International Journal of Pharmaceutics

Volumn 436, Issue 1-2, 2012, Pages 652-658

  Park, Chun Woong ^a,b   Mansour, Heidi M ^c   Oh, Tack Oon ^a   Kim, Ju Young ^a   Ha, Jung Myung ^a   Lee, Beom Jin ^d   Chi, Sang Cheol ^a   Rhee, Yun Seok ^e   Park, Eun Seok ^a  

^a Sungkyunkwan University   (South Korea)

^b Chungbuk National University   (South Korea)

^c UNIVERSITY OF KENTUCKY   (United States)

^d Ajou University   (South Korea)

^e Gyeongsang National University   (South Korea)

Author keywords

Eutectic mixture; Itraconazole; Phenol; Skin permeation; Topical

Indexed keywords

BENZYL ALCOHOL; CARBONYL DERIVATIVE; HYDROXYL GROUP; ITRACONAZOLE; OLEIC ACID; PHENOL;

ANIMAL TISSUE; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; FEASIBILITY STUDY; HAIRLESS MOUSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROGEN BOND; HYDROPHOBICITY; INFRARED SPECTROSCOPY; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PHYSICAL PHASE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; X RAY POWDER DIFFRACTION;

ANIMALS; ITRACONAZOLE; MALE; MICE; MICE, HAIRLESS; MICE, INBRED ICR; PHENOL; SKIN; SKIN ABSORPTION;

EID: 84865304491     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.07.054     Document Type: Article

References (39)

1. S.M. Abdel-Rahman, R.F. Jacobs, J. Massarella, R.E. Kauffman, J.S. Bradley, H.C. Kimko, G.L. Kearns, K. Shalayda, C. Curtin, S.D. Maldonado, and J.L. Blumer Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents Antimicrob. Agents Chemother. 51 2007 2668 2673
2. A.H. Al-Marzouqi, I. Shehatta, B. Jobe, and A. Dowaidar Phase solubility and inclusion complex of itraconazole with beta-cyclodextrin using supercritical carbon dioxide J. Pharm. Sci. 95 2006 292 304
3. E. Anaissie Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review Clin. Infect. Dis. 14 Suppl. 1 1992 S43L 53
4. B.W. Barry Dermatological Formulations: Percutaneous Absorption 1983 Marcel Dekker Inc. New York
5. C.R. Bradford, A.G. Prentice, D.W. Warnock, and J.A. Copplestone Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia J. Antimicrob. Chemother. 28 1991 555 560
6. M.E. Brewster, R. Vandecruys, J. Peeters, P. Neeskens, G. Verreck, and T. Loftsson Comparative interaction of 2-hydroxypropyl-beta-cyclodextrin and sulfobutylether-beta-cyclodextrin with itraconazole: phase-solubility behavior and stabilization of supersaturated drug solutions Eur. J. Pharm. Sci. 34 2008 94 103
7. C.M. Buchanan, N.L. Buchanan, K.J. Edgar, S. Klein, J.L. Little, M.G. Ramsey, K.M. Ruble, V.J. Wacher, and M.F. Wempe Pharmacokinetics of itraconazole after intravenous and oral dosing of itraconazole-cyclodextrin formulations J. Pharm. Sci. 96 2007 3100 3116
8. H.J. Cho, K.Y. Kyong, G.W. Lee, and U.K. Jee Formulation design and evaluation of niosome containing itraconazole for dermal delivery system J. Korean Pharm. Sci. 35 2005 165 171
9. K.P. Chowdary, and S.S. Rao Investigation of dissolution enhancement of itraconazole by solid dispersion in superdisintegrants Drug Dev. Ind. Pharm. 26 2000 1207 1211
10. J.A. Como, and W.E. Dismukes Oral azole drugs as systemic antifungal therapy N. Engl. J. Med. 330 1994 263 272
11. F. Damian, N. Blaton, L. Naesens, J. Balzarini, R. Kinget, P. Augustijns, and G. Van den Mooter Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14 Eur. J. Pharm. Sci. 10 2000 311 322
12. K. De Beule Itraconazole: pharmacology, clinical experience and future development Int. J. Antimicrob. Agents 6 1996 175 181
13. K. De Beule, P. De Doncker, G. Cauwenbergh, M. Koster, R. Legendre, N. Blatchford, J. Daunas, and E. Chwetzoff The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987) Mycoses 31 1988 476 485
14. S. deChasteigner, H. Fessi, J.P. Devissaguet, and F. Puisieux Comparative study of the association of itraconazole with colloidal drug carriers Drug Dev. Res. 38 1996 125 133
15. B. Dupont Itraconazole therapy in aspergillosis: study in 49 patients J. Am. Acad. Dermatol. 23 1990 607 614
16. M. Francois, E. Snoeckx, P. Putteman, F. Wouters, E. De Proost, U. Delaet, J. Peeters, and M.E. Brewster A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole AAPS PharmSci 5 2003 E5
17. K. Isama, S. Kojima, and A. Nakamura Phase studies of a urethane model compound and polyether macroglycols by infrared spectroscopy and the relationship between eutectic composition of soft segment and blood compatibility J. Biomed. Mater. Res. 27 1993 539 545
18. J.Y. Jung, S.D. Yoo, S.H. Lee, K.H. Kim, D.S. Yoon, and K.H. Lee Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique Int. J. Pharm. 187 1999 209 218
19. R. Kaur, D.J.W. Grant, and T. Eaves Comparison of polyethylene glycol and polyoxyethylene stearate as excipients for solid dispersion systems of griseofulvin and tolbutamide I: phase equilibria J. Pharm. Sci. 69 1980 1317 1321
20. J.E. Kipp The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs Int. J. Pharm. 284 2004 109 122
21. E.A. Lee, S.K. Heo, M.J. Choi, S.J. Chung, C.K. Shim, and D.D. Kim Formulations of itraconazole for topical skin delivery J. Korean Pharm. Sci. 37 2007 167 171
22. M. Martinez-Ramos, B.J. Claros, M.A. Vale-Oviedo, E. Siso-Villarroel, R. Padilla, A. Santiago, and J.A. Simon Effect of the vehicle on the topical itraconazole efficacy for treating corneal ulcers caused by Aspergillus fumigatus Clin. Exp. Ophthalmol. 36 2008 335 338
23. D.I. Nesseem Formulation and evaluation of itraconazole via liquid crystal for topical delivery system J. Pharm. Biomed. Anal. 26 2001 387 399
24. B. Rabinow, J. Kipp, P. Papadopoulos, J. Wong, J. Glosson, J. Gass, C.S. Sun, T. Wielgos, R. White, C. Cook, K. Barker, and K. Wood Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat Int. J. Pharm. 339 2007 251 260
25. Y.S. Rhee, C.W. Park, T.Y. Nam, Y.S. Shin, S.C. Chi, and E.S. Park Formulation of parenteral microemulsion containing itraconazole Arch. Pharm. Res. 30 2007 114 123
26. R.M. Silverstein, G.C. Bassler, and T.C. Morrill Proton magnetic resonance spectrometry D. Sawicki, Spectrometric Identification of Organic Compounds 1991 John Wiley & Sons, Inc. New York
27. K. Six, G. Verreck, J. Peeters, P. Augustijns, R. Kinget, and G. Van den Mooter Characterization of glassy itraconazole: a comparative study of its molecular mobility below T(g) with that of structural analogues using MTDSC Int. J. Pharm. 213 2001 163 173
28. P.W. Stott, A.C. Williams, and B.W. Barry Transdermal delivery from eutectic systems: enhanced permeation of a model drug, ibuprofen J. Control. Release 50 1998 297 308
29. J.L. Tang, H. Wei, H.M. Liu, H.Y. Ji, D. Dong, D.L. Zhu, and L.H. Wu Pharmacokinetics and biodistribution of itraconazole in rats and mice following intravenous administration in a novel liposome formulation Drug Deliv. 17 2010 223 230
30. G. Tricot, E. Joosten, M.A. Boogaerts, J. Vande Pitte, and G. Cauwenbergh Ketoconazole vs itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies Rev. Infect. Dis. 9 Suppl. 1 1987 S94L 99
31. J. Van Cutsem, F. Van Gerven, M.A. Van de Ven, M. Borgers, and P.A. Janssen Itraconazole, a new triazole that is orally active in aspergillosis Antimicrob. Agents Chemother. 26 1984 527 534
32. I. Weuts, D. Kempen, K. Six, J. Peeters, G. Verreck, M. Brewster, and G. Van den Mooter Evaluation of different calorimetric methods to determine the glass transition temperature and molecular mobility below T(g) for amorphous drugs Int. J. Pharm. 259 2003 17 25
33. W. Yang, K.P. Johnston, and R.O. Williams 3rd Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats Eur. J. Pharm. Biopharm. 75 2010 33 41
34. W. Yang, J. Tam, D.A. Miller, J. Zhou, J.T. McConville, K.P. Johnston, and R.O. Williams High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers Int. J. Pharm. 361 2008 177 188
35. W.W. Yao, T.C. Bai, J.P. Sun, C.W. Zhu, J. Hu, and H.L. Zhang Thermodynamic properties for the system of silybin and poly(ethylene glycol) 6000 Thermochim. Acta 437 2005 17 20
36. G. Ye, S. Wang, P.W. Heng, L. Chen, and C. Wang Development and optimization of solid dispersion containing pellets of itraconazole prepared by high shear pelletization Int. J. Pharm. 337 2007 80 87
37. Y. Yi, H.J. Yoon, B.O. Kim, M. Shim, S.O. Kim, S.J. Hwang, and M.H. Seo A mixed polymeric micellar formulation of itraconazole: characteristics, toxicity and pharmacokinetics J. Control. Release 117 2007 59 67
38. S.D. Yoo, E. Kang, H. Jun, B.S. Shin, K.C. Lee, and K.H. Lee Absorption, first-pass metabolism, and disposition of itraconazole in rats Chem. Pharm. Bull. (Tokyo) 48 2000 798 801
39. S.D. Yoo, S.H. Lee, E. Kang, H. Jun, J.Y. Jung, J.W. Park, and K.H. Lee Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles Drug Dev. Ind. Pharm. 26 2000 27 34